Want to see ZVRA full AI Analyst Report?
ZVRA Stock Chart & Stats
$10.67
$0.38(4.61%)
At close: 4:00 PM EST
$10.67
$0.38(4.61%)
Day’s Range― - ―
52-Week Range$7.16 - $15.04
Previous CloseN/A
Volume189.47K
Average Volume (3M)1.43M
Market Cap
$717.66M
Enterprise Value$361.88
Total Cash (Recent Filing)$95.59M
Total Debt (Recent Filing)$1.15M
Price to Earnings (P/E)5.7
Beta0.86
Next Earnings
Aug 05, 2026EPS Estimate
0.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.18
Shares Outstanding59,115,086
10 Day Avg. Volume1,090,161
30 Day Avg. Volume1,430,644
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)3.20
Price to Sales (P/S)4.65
P/FCF Ratio-203.69
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$28.25Price Target Upside164.76% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)1.07
Revenue Forecast (FY)$145.74M
Bulls Say, Bears Say
Bulls Say
Commercial Revenue GrowthSustained, rapid top-line growth driven by MIPLYFFA indicates durable commercial traction in a specialty orphan market where treatment uptake and reimbursement are sticky. Strong early sales validate prescriber adoption and support recurring product sales as a long-term revenue base.
Delevered Balance Sheet & Cash RunwayA debt-free balance sheet with ~$237M in cash provides material runway for commercialization, regulatory milestones and trial execution while lowering refinancing risk. Eliminating interest expense (~$8M/yr saved) improves durable financial flexibility for strategic investments.
Clinical Validation & Guideline InclusionGuideline inclusion and a multi-year dataset across >270 patients create a structural competitive advantage: they support payer coverage, prescriber confidence and barriers to entry. This clinical validation underpins sustainable demand in a small, well-defined orphan population.
Bears Say
Underlying Operating ProfitabilityDespite reported net income, persistent negative operating profit indicates core activities (product gross margin less opex) are not yet self-sustaining. Reliance on non-operating items to reach GAAP profitability raises risk that earnings may reverse if one-time benefits are not repeatable.
Weak Cash Conversion QualityOperating cash flow remains small relative to reported earnings (coverage ~0.27) and free cash flow has been volatile. Earnings that are not well converted to cash reduce funding predictability for commercialization and trials, increasing reliance on financing or asset sales.
Slow Pivotal Trial Event AccrualAn event-driven Phase III with only 2 of 28 events accrued suggests prolonged timelines for readouts and regulatory decisions. Slower trial progress increases execution risk, defers potential label expansion or commercial upside, and can raise incremental development costs over time.
Zevra Therapeutics News
ZVRA FAQ
What was Zevra Therapeutics, Inc.’s price range in the past 12 months?
Zevra Therapeutics, Inc. lowest stock price was $7.16 and its highest was $15.04 in the past 12 months.
What is Zevra Therapeutics, Inc.’s market cap?
Zevra Therapeutics, Inc.’s market cap is $717.66M.
When is Zevra Therapeutics, Inc.’s upcoming earnings report date?
Zevra Therapeutics, Inc.’s upcoming earnings report date is Aug 05, 2026 which is in 11 days.
How were Zevra Therapeutics, Inc.’s earnings last quarter?
Zevra Therapeutics, Inc. released its earnings results on May 06, 2026. The company reported $0.6 earnings per share for the quarter, beating the consensus estimate of $0.081 by $0.519.
Is Zevra Therapeutics, Inc. overvalued?
According to Wall Street analysts Zevra Therapeutics, Inc.’s price is currently Undervalued.
Does Zevra Therapeutics, Inc. pay dividends?
Zevra Therapeutics, Inc. does not currently pay dividends.
What is Zevra Therapeutics, Inc.’s EPS estimate?
Zevra Therapeutics, Inc.’s EPS estimate is 0.11.
How many shares outstanding does Zevra Therapeutics, Inc. have?
Zevra Therapeutics, Inc. has 59,115,086 shares outstanding.
What happened to Zevra Therapeutics, Inc.’s price movement after its last earnings report?
Zevra Therapeutics, Inc. reported an EPS of $0.6 in its last earnings report, beating expectations of $0.081. Following the earnings report the stock price went down -2.222%.
Which hedge fund is a major shareholder of Zevra Therapeutics, Inc.?
Currently, no hedge funds are holding shares in ZVRA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Zevra Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$28.25 (164.76% Upside)
$28.25 (164.76% Upside)
Blogger Sentiment
Bullish
ZVRA Sentiment 70%
Sector Average 65%
Sector Average 65%
Hedge Fund Trend
Increased
By 113.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.3%
Last 30 Days ▼ 2.6%
Last 30 Days ▼ 2.6%
News Sentiment
Very Bearish
Bullish news 17%
Bearish news 83%
Bearish news 83%
Technicals
SMA
Positive
20 days / 200 days
Momentum
6.37%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
61.30%
Trailing 12-Months
Company Description
Zevra Therapeutics, Inc.
Zevra Therapeutics, Inc., founded in 2006 and based in Celebration, Florida, is a biopharmaceutical company dedicated to discovering and developing innovative treatments for rare diseases. The company employs its proprietary Ligand Activated Therapy (LAT) technology to create novel prodrug versions of existing FDA-approved medications or to enable new applications for other compounds, primarily addressing serious medical conditions within the United States. Zevra's development pipeline is strategically concentrated on high-unmet-need therapeutic areas, including attention deficit hyperactivity disorder (ADHD), stimulant use disorder, and various rare central nervous system (CNS) conditions, such as idiopathic hypersomnia (IH). Their lead product candidate, KP1077, which is a prodrug of d-methylphenidate (known as serdexmethylphenidate), is currently in Phase II clinical trials for the treatment of both IH and narcolepsy. Another key prodrug candidate, KP879, is also advancing through Phase II studies for stimulant use disorder. In addition to its pipeline, Zevra has successfully secured FDA approval for two products: AZSTARYS, a once-daily treatment for ADHD in patients aged six years and older, and APADAZ, an immediate-release combination product containing benzhydrocodone (a prodrug of hydrocodone) and acetaminophen. The company's product portfolio also includes arimoclomol, and it holds collaboration and licensing agreements with KVK-Tech, Inc. and Commave Therapeutics SA. Formerly known as KemPharm, Inc., the company officially rebranded to Zevra Therapeutics, Inc. in February 2023.
ZVRA Stock 12 Month Forecast
Average Price Target
$28.25
▲(164.76% Upside)
Technical Analysis
Lexicon Pharmaceuticals
―
Prothena
―
Ocugen
―
Corvus Pharmaceuticals
―
Solid Biosciences
―
Ownership Overview
1.49% Insiders
13.31% Mutual Funds
0.93% Other Institutional Investors
68.53% Public Companies and Individual Investors